Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Apoptosis

A new matrix metalloproteinase inhibitor SI-27 induces apoptosis in several human myeloid leukemia cell lines and enhances sensitivity to TNF alpha-induced apoptosis

Leukemia volume 15, pages 1217–1224 (2001)Cite this article

Abstract

MMP inhibitors are used clinically for the stabilization of tumor growth, thus prolonging survival in cancer patients. However, their role in the treatment of hematopoietic malignancies remains unclear. In the present study, we investigated the effects of a new MMP inhibitor, SI-27, in hematopoietic malignancies. SI-27 alone induces apoptosis in several human myeloid leukemia cell lines such as U937, NB4, and HL60 cells by activating caspase 8, 9, and 3. Apoptosis was measured with annexin V positive staining, a drop in mitochondrial transmembrane potential (ΔΨm), presence of hypodiploid DNA, and cleavage of PARP and IκBα. Furthermore, at lowered concentrations, which did not directly induce apoptosis, SI-27 acted to sensitize U937 cells and other cells to tumor necrosis factor α (TNF-α)-mediated apoptosis. The accumulation of membrane Fas, the Fas ligand, and TNFR1 were not apparent due to exposure to SI-27, and antagonistic anti-Fas or anti-Fas ligand antibodies did not block SI-27-induced apoptosis. Thus, SI-27-induced apoptosis is not mediated by the Fas pathway. These results suggest that MMP inhibitors, alone or in combination with other cytotoxic agents, can provide a unique method for treating acute myeloid leukemia, refractory to classical anti-cancer drugs, and may thus suppress recurrence.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Massova I, Kotra LP, Fridman R, Mobashery S . Matrix metalloproteinases: structures, evolution, and diversification FASEB J 1998 12: 1075–1095

    Article  CAS  PubMed  Google Scholar 

  2. Werb Z . ECM and cell surface proteolysis: regulating cellular ecology Cell 1997 91: 439–442

    Article  CAS  PubMed  Google Scholar 

  3. Goetzl EJ, Banda MJ, Leppert D . Matrix metalloproteinases in immunity J Immunol 1996 156: 1–4

    CAS  PubMed  Google Scholar 

  4. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z . The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis Cell 1999 98: 137–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Stetler-Stevenson WG . Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention J Clin Invest 1999 103: 1237–1241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chambers AF, Matrisian LM . Changing views of the role of matrix metalloproteinases in metastasis J Natl Cancer Inst 1997 89: 1260–1270

    Article  CAS  PubMed  Google Scholar 

  7. Denis LJ, Verweij J . Matrix metalloproteinase inhibitors: present achievements and future prospects Invest New Drugs 1997 15: 175–185

    Article  CAS  PubMed  Google Scholar 

  8. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ . Matrix metalloproteinase inhibitors Invest New Drugs 1997 15: 61–75

    Article  CAS  PubMed  Google Scholar 

  9. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ . Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer J Clin Oncol 1998 16: 2150–2156

    Article  CAS  PubMed  Google Scholar 

  10. Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, Turner AR, Zhang MC, Edwards DR, Kossakowska AE . Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells Br J Haematol 1999 105: 402–411

    Article  CAS  PubMed  Google Scholar 

  11. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr . Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB Nat Med 1999 5: 412–417

    Article  PubMed  Google Scholar 

  12. Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S, Okuyama A . Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor Int J Cancer 1994 58: 730–735

    Article  CAS  PubMed  Google Scholar 

  13. Cawston TE, Barrett AJ . A rapid and reproducible assay for collagenase using [1–14C]acetylated collagen Anal Biochem 1979 99: 340–345

    Article  CAS  PubMed  Google Scholar 

  14. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Meth 1991 139: 271–279

    Article  CAS  Google Scholar 

  15. Macho A, Decaudin D, Castedo M, Hirsch T, Susin SA, Zamzami N, Kroemer G . Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis Cytometry 1996 25: 333–340

    Article  CAS  PubMed  Google Scholar 

  16. Beg AA, Baltimore D . An essential role for NF-kappaB in preventing TNF-alpha-induced cell death Science 1996 274: 782–784

    Article  CAS  PubMed  Google Scholar 

  17. Barkett M, Xue D, Horvitz HR, Gilmore TD . Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro J Biol Chem 1997 272: 29419–29422

    Article  CAS  PubMed  Google Scholar 

  18. Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM . Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures J Clin Invest 1996 97: 2833–2841

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S . The Fas ligand in human serum Nat Med 1996 2: 317–322

    Article  CAS  PubMed  Google Scholar 

  20. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S . Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models Cancer Res 1999 59: 1252–1258

    CAS  PubMed  Google Scholar 

  21. Mitsiades N, Poulaki V, Leone A, Tsokos M . Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors J Natl Cancer Inst 1999 91: 1678–1684

    Article  CAS  PubMed  Google Scholar 

  22. Friesen C, Herr I, Krammer PH, Debatin KM . Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells Nat Med 1996 2: 574–577

    Article  CAS  PubMed  Google Scholar 

  23. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K . Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction Blood 1999 93: 3053–3063

    CAS  PubMed  Google Scholar 

  24. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH . Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/the Fas ligand interactions Blood 1997 90: 935–943

    CAS  PubMed  Google Scholar 

  25. Sekine K, Fujii H, Abe F . Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines Leukemia 1999 13: 729–734

    Article  CAS  PubMed  Google Scholar 

  26. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, 3rd . Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 1994 331: 896–903

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the Research Foundation for Community Medicine.

Author information

Authors and Affiliations

  1. Third Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan

    Y Nakamura, K Sato, N Wakimoto, F Kimura & K Motoyoshi

  2. Banyu Tsukuba Research Institute, Tsukuba, Ibaragi, Japan

    A Okuyama

Authors
  1. Y Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Wakimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Okuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Motoyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, Y., Sato, K., Wakimoto, N. et al. A new matrix metalloproteinase inhibitor SI-27 induces apoptosis in several human myeloid leukemia cell lines and enhances sensitivity to TNF alpha-induced apoptosis. Leukemia 15, 1217–1224 (2001). https://doi.org/10.1038/sj.leu.2402187

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402187

Keywords

This article is cited by

Search

Advanced search

Quick links